CISC 2021 Meeting Harnessing Imaging Tools to Guide Immunotherapy Trials Registration Information



← Reply ≪ Reply All → Forward ...

CISC 2021 Meeting Harnessing Imaging Tools to Guide Immunotherapy Trials is taking place as a virtual meeting on April 6, 2021. The meeting will take place beginning at 9:30 am on April 6, a draft agenda is attached for your reference. You are invited to attend and contribute to this meeting as a participant.

Participation in this meeting is by invitation only. Please go to https://www.cvent.com/d/cjqs5d to register for this meeting so that we can plan for your attendance. We request your response no later than April 2, 2021. If you are unable to attend this meeting, kindly respond to this email.

Information on the WebEx log in will be provided closer to the meeting date and only to registered participants.

The objectives of this meeting are:

- To review the available diagnostic imaging tools to assess the impact of immunotherapy. This includes the role of predicting as well as assessing response in Phase II and III immunotherapy clinical trials.
- Assessing the role of investigational tools such as:
 - o Image analysis of standard of care scans such as CT, MR and PET texture, volume and radiomics
 - o Functional MR agents such as USPIOs
 - Molecular Imaging PET agents

I look forward to seeing you in April!

Natalie

Natalie Fielman (Contractor)

Senior Program Coordinator
Clinical Monitoring Research Program Directorate (CMRPD)
Frederick National Laboratory for Cancer Research
Leidos Biomedical Research, Inc.
Support to: National Cancer Institute, Office of the Director
Coordinating Center for Clinical Trials (CCCT)
9609 Medical Center Drive, Room 6W-616
Bethesda, MD 20892-0744
(for express mail and courier delivery: Rockville, MD 20850)

Phone: 240-276-6846

Cell: 240-656-9261 Fax: (240) 276-7397

e-mail: natalie.fielman@nih.gov

This e-mail and any attachments to it are intended only for the identified recipients. It may contain proprietary or otherwise legally protected information for Leidos Biomedical Research, Inc. Any unauthorized use or disclosure of this communication is strictly prohibited. If you received this communication in error, please notify the sender and delete or otherwise destroy the e-mail and all attachments immediately